- AuthorisedTherapeutic exploratory (Phase II)
A phase II study of ficerafusp alfa (BCA 101) in combination with nivolumab in platinum refractory head and neck squamous cell carcinoma patients who progressed within 6 months after multimodal treatment for locally advanced disease ( BICARA)
This study is testing a new combination treatment, Ficerafusp Alfa and Nivolumab, for a type of head and neck cancer. It's for patients whose cancer has come back or worsened after previous treatments. Researchers want to see how well this new treatment shrinks the cancer.
For: head and neck squamous cell carcinomaFrance - RecruitingPHASE2, PHASE3
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
This study looks at a new drug, ficerafusp alfa, combined with pembrolizumab (Keytruda®) for people with advanced head and neck cancer. It compares this combination against pembrolizumab alone to see if it works better and is safe.
For: Metastatic Head and Neck Squamous Cell Carcinoma · Recurrent Head and Neck Squamous Cell CarcinomaUnited States · Argentina · Australia